The Effect of JAK Inhibitor Tofacitinib on Chondrocyte Autophagy
Ping Zhang1, Juan Xiao1, Chenggen Luo1
1Department of Rheumatology and Immunology, Affiliated Hospital of Zunyi Medical University, Huichuan District, 149 Dalian Road, Zunyi, 563003, China.
Abstract:
Osteoarthritis (OA) is a multifactorial disease of the whole joint that has a complex pathogenesis. There is currently no cure for OA. Tofacitinib is a broad JAK inhibitor that can have an anti-inflammatory effect. The objective of this study was to investigate the effect of tofacitinib on the cartilage extracellular matrix in OA and determine whether tofacitinib exerts a protective effect by inhibiting the JAK1/STAT3 signaling pathway and upregulating autophagy in chondrocytes. We investigated the expression profile of OA in vitro by exposing SW1353 cells to interleukin-1β (IL-1β), and induced OA in vivo using the modified Hulth method in rats. We found that IL-1β promoted the expression of OA-related matrix metalloproteinases (MMP3 and MMP13), reduced the expression of collagen II, reduced the expression of beclin1 and LC3-II/I, and promoted the accumulation of p62 in SW1353 cells. Tofacitinib attenuated IL-1β-stimulated changes in MMPs and collagen II and restored autophagy. In IL-1β-stimulated SW1353 cells, the JAK1/STAT3 signaling pathway was activated. Tofacitinib inhibited the IL-1β-stimulated expression of p-JAK1 and p-STAT3 and prevented translocation of p-STAT3 to the nucleus. In the rat model of OA, tofacitinib reduced articular cartilage degeneration by delaying cartilage extracellular matrix degradation and increasing chondrocyte autophagy. Our study demonstrates that chondrocyte autophagy was impaired in experimental models of OA. Tofacitinib reduced the inflammatory response and restored the damaged autophagic flux in OA.
Insights
Tofacitinib, a JAK inhibitor, shows promise in treating osteoarthritis (OA) by reducing inflammation and restoring cartilage health. It protects cartilage extracellular matrix and enhances chondrocyte autophagy in OA models.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Osteoarthritis (OA) is a degenerative joint disease with no current cure.
- The pathogenesis of OA involves complex inflammatory and matrix degradation processes.
- Janus kinase (JAK) inhibitors, like tofacitinib, possess anti-inflammatory properties.
Purpose of the Study:
- To investigate tofacitinib's effect on cartilage extracellular matrix in OA.
- To determine if tofacitinib protects chondrocytes by inhibiting JAK1/STAT3 signaling and upregulating autophagy.
- To evaluate tofacitinib's therapeutic potential in experimental OA models.
Main Methods:
- In vitro OA model using SW1353 cells stimulated with interleukin-1β (IL-1β).
- In vivo OA model induced by the modified Hulth method in rats.
- Analysis of matrix metalloproteinases (MMPs), collagen II, autophagy markers (beclin1, LC3-II/I, p62), and JAK1/STAT3 pathway activation.
Main Results:
- IL-1β induced OA-like changes in vitro, increasing MMPs and decreasing collagen II and autophagy markers.
- Tofacitinib treatment attenuated IL-1β-induced matrix degradation and restored autophagy in vitro.
- Tofacitinib inhibited the JAK1/STAT3 pathway activation and nuclear translocation of p-STAT3.
- In vivo, tofacitinib reduced cartilage degeneration and enhanced chondrocyte autophagy in a rat OA model.
Conclusions:
- Chondrocyte autophagy is impaired in experimental OA models.
- Tofacitinib demonstrates a protective effect against cartilage degeneration in OA.
- Tofacitinib reduces inflammation and restores autophagic flux in OA by inhibiting the JAK1/STAT3 pathway.
Related Concept Videos
The JAK-STAT Signaling Pathway
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
TGF - β Signaling Pathway
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
PI3K/mTOR/AKT Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...


